company background image
ABVX

ABIVAX Société Anonyme ENXTPA:ABVX Stock Report

Last Price

€17.92

Market Cap

€300.2m

7D

0.7%

1Y

-36.0%

Updated

27 May, 2022

Data

Company Financials +
ABVX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth3/6
Past Performance0/6
Financial Health4/6
Dividends0/6

ABVX Stock Overview

ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France.

ABIVAX Société Anonyme Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for ABIVAX Société Anonyme
Historical stock prices
Current Share Price€17.92
52 Week High€36.70
52 Week Low€15.58
Beta1.35
1 Month Change-7.34%
3 Month Change-13.64%
1 Year Change-36.00%
3 Year Change98.23%
5 Year Change31.77%
Change since IPO-14.67%

Recent News & Updates

Shareholder Returns

ABVXFR BiotechsFR Market
7D0.7%-0.4%3.7%
1Y-36.0%-39.4%-3.7%

Return vs Industry: ABVX exceeded the French Biotechs industry which returned -41.6% over the past year.

Return vs Market: ABVX underperformed the French Market which returned -5.9% over the past year.

Price Volatility

Is ABVX's price volatile compared to industry and market?
ABVX volatility
ABVX Average Weekly Movement10.0%
Biotechs Industry Average Movement8.8%
Market Average Movement5.9%
10% most volatile stocks in FR Market10.0%
10% least volatile stocks in FR Market3.4%

Stable Share Price: ABVX is more volatile than 75% of French stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: ABVX's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of French stocks.

About the Company

FoundedEmployeesCEOWebsite
201324Hartmut Ehrlichhttps://www.abivax.com

ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn’s Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer.

ABIVAX Société Anonyme Fundamentals Summary

How do ABIVAX Société Anonyme's earnings and revenue compare to its market cap?
ABVX fundamental statistics
Market Cap€300.25m
Earnings (TTM)-€41.36m
Revenue (TTM)n/a

0.0x

P/S Ratio

-7.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ABVX income statement (TTM)
Revenue€0
Cost of Revenue€45.52m
Gross Profit-€45.52m
Other Expenses-€4.16m
Earnings-€41.36m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

Sep 15, 2022

Earnings per share (EPS)-2.47
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio150.1%

How did ABVX perform over the long term?

See historical performance and comparison

Valuation

Is ABIVAX Société Anonyme undervalued compared to its fair value and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: ABVX (€17.92) is trading below our estimate of fair value (€67.98)

Significantly Below Fair Value: ABVX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ABVX is unprofitable, so we can't compare its Price-To-Earnings Ratio to the European Biotechs industry average.

PE vs Market: ABVX is unprofitable, so we can't compare its Price-To-Earnings Ratio to the French market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ABVX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ABVX is overvalued based on its Price-To-Book Ratio (8.4x) compared to the FR Biotechs industry average (2.8x).


Future Growth

How is ABIVAX Société Anonyme forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

Future Growth Score

3/6

Future Growth Score 3/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


47.7%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ABVX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.3%).

Earnings vs Market: ABVX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ABVX's is expected to become profitable in the next 3 years.

Revenue vs Market: ABVX is forecast to have no revenue next year.

High Growth Revenue: ABVX is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ABVX's Return on Equity is forecast to be high in 3 years time


Past Performance

How has ABIVAX Société Anonyme performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-29.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ABVX is currently unprofitable.

Growing Profit Margin: ABVX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ABVX is unprofitable, and losses have increased over the past 5 years at a rate of 29% per year.

Accelerating Growth: Unable to compare ABVX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ABVX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).


Return on Equity

High ROE: ABVX has a negative Return on Equity (-116.13%), as it is currently unprofitable.


Financial Health

How is ABIVAX Société Anonyme's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ABVX's short term assets (€75.2M) exceed its short term liabilities (€36.5M).

Long Term Liabilities: ABVX's short term assets (€75.2M) exceed its long term liabilities (€38.2M).


Debt to Equity History and Analysis

Debt Level: ABVX has more cash than its total debt.

Reducing Debt: ABVX's debt to equity ratio has increased from 0.6% to 150.1% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ABVX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ABVX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is ABIVAX Société Anonyme current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ABVX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ABVX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ABVX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ABVX's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ABVX has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

5.3yrs

Average management tenure


CEO

Hartmut Ehrlich

8.42yrs

Tenure

€464,408

Compensation

Prof. Dr. Hartmut J. Ehrlich, M.D. has been the Chief Executive Officer of ABIVAX S.A. since December 04, 2013. Prof. Dr. Ehrlich is a physician and global leader with 30 years in academia and in the biop...


CEO Compensation Analysis

Compensation vs Market: Hartmut's total compensation ($USD497.54K) is about average for companies of similar size in the French market ($USD479.65K).

Compensation vs Earnings: Hartmut's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: ABVX's management team is seasoned and experienced (5.3 years average tenure).


Board Members

Experienced Board: ABVX's board of directors are considered experienced (7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.9%.


Top Shareholders

Company Information

ABIVAX Société Anonyme's employee growth, exchange listings and data sources


Key Information

  • Name: ABIVAX Société Anonyme
  • Ticker: ABVX
  • Exchange: ENXTPA
  • Founded: 2013
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: €300.249m
  • Shares outstanding: 16.75m
  • Website: https://www.abivax.com

Number of Employees


Location

  • ABIVAX Société Anonyme
  • 5, rue de la Baume
  • Paris
  • Ile-de-France
  • 75008
  • France

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/27 00:00
End of Day Share Price2022/05/27 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.